GT BIOPHARMA, INC. Net Change in Cash
GT BIOPHARMA, INC. (GTBP) reported Net Change in Cash of -$1.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-14
- GT BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $2.11M.
- GT BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$1.59M, a 282.09% decline year-over-year.
- GT BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $871.00K.
- GT BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$3.63M.
- GT BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $2.86M, a 3.51% decline from fiscal 2024.
- GT BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $2.96M.
- GT BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$4.59M.
- GT BIOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$3.30M, a 189.78% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.85M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $2.11M 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $2.86M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | -$1.42M 10-Q/A · filed 2026-03-06 | |||
| 2025-06-30 | $1.28M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$1.59M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $2.96M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $5.43M 10-Q/A · filed 2026-03-06 | |||
| 2024-06-30 | $8.17M 10-Q/A · filed 2026-03-06 | |||
| 2024-03-31 | $871.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$4.59M 10-K · filed 2025-02-21 | |||
| 2023-09-30 | -$3.02M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$2.90M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$3.63M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$3.30M 10-K · filed 2024-03-26 | |||
| 2022-09-30 | -$6.50M 10-Q · filed 2023-11-01 | |||
| 2022-06-30 | -$3.61M 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | -$1.68M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $3.67M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $4.38M 10-Q · filed 2022-10-31 | |||
| 2021-06-30 | $34.21M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $22.26M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $5.27M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |